Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Cell Pathways and Glaxo Wellcome to study Aptosyn/Navelbine combination for NSCLC

July 21, 2000

Indena's new colchicine derivatives active against multidrug-resistant cancer cells

July 20, 2000

Arsenic trioxide receives third orphan drug designation from FDA

July 20, 2000

Photofrin approved in Sweden, Ireland and Italy

July 20, 2000

Onyx and Bayer begin clinical testing of Ras inhibitor

July 19, 2000

Synthesis, activity and use of new neovascularization inhibitors disclosed by Takeda

July 19, 2000

G-protein-targeted antisense oligonucleotides patented by Isis

July 19, 2000

Intranasal IM-862 effective and safe in patients with AIDS-related Kaposi's sarcoma

July 19, 2000

Tularik initiates phase II studies of T-64 for treatment of solid tumors

July 19, 2000

Novel nucleoside transport inhibitor NU-3108 deemed suitable for further development

July 18, 2000

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 13, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...